Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200211678> ?p ?o ?g. }
- W4200211678 endingPage "112460" @default.
- W4200211678 startingPage "112460" @default.
- W4200211678 abstract "Familial hypercholesterolemia (FH) is associated with low-grade systemic inflammation, a key driver of premature atherosclerosis. We investigated the effects of inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) function on inflammatory state, endothelial dysfunction and cardiovascular outcomes in patients with FH. Fourteen patients with FH were evaluated before and 8 weeks after administration of a PCSK9 blocking monoclonal antibody (alirocumab, 150 mg/subcutaneous/14 days). In vivo and ex vivo analysis revealed that alirocumab blunted the attachment of leukocytes to TNFα-stimulated human umbilical arterial endothelial cells (HUAEC) and suppressed the activation of platelets and most leukocyte subsets, which was accompanied by the diminished expression of CX3CR1, CXCR6 and CCR2 on several leukocyte subpopulations. By contrast, T-regulatory cell activation was enhanced by alirocumab treatment, which also elevated anti-inflammatory IL-10 plasma levels and lowered circulating pro-inflammatory cytokines. Plasma levels of IFNγ positively correlated with levels of total and LDL-cholesterol, whereas circulating IL-10 levels negatively correlated with these key lipid parameters. In vitro analysis revealed that TNFα stimulation of HUAEC increased the expression of PCSK9, whereas endothelial PCSK9 silencing reduced TNFα-induced mononuclear cell adhesion mediated by Nox5 up-regulation and p38-MAPK/NFκB activation, concomitant with reduced SREBP2 expression. PCSK9 silencing also decreased endothelial CX3CL1 and CXCL16 expression and chemokine generation. In conclusion, PCSK9 inhibition impairs systemic inflammation and endothelial dysfunction by constraining leukocyte-endothelium interactions. PCSK9 blockade may constitute a new therapeutic approach to control the inflammatory state associated with FH, preventing further cardiovascular events in this cardiometabolic disorder." @default.
- W4200211678 created "2021-12-31" @default.
- W4200211678 creator A5001713307 @default.
- W4200211678 creator A5008140876 @default.
- W4200211678 creator A5021398141 @default.
- W4200211678 creator A5060371031 @default.
- W4200211678 creator A5064239944 @default.
- W4200211678 creator A5069220879 @default.
- W4200211678 creator A5076327210 @default.
- W4200211678 creator A5087845262 @default.
- W4200211678 date "2022-01-01" @default.
- W4200211678 modified "2023-10-17" @default.
- W4200211678 title "Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players" @default.
- W4200211678 cites W1966492350 @default.
- W4200211678 cites W1969093165 @default.
- W4200211678 cites W1980550449 @default.
- W4200211678 cites W2001732177 @default.
- W4200211678 cites W2005745212 @default.
- W4200211678 cites W2021283737 @default.
- W4200211678 cites W2021878270 @default.
- W4200211678 cites W2031397753 @default.
- W4200211678 cites W2033669311 @default.
- W4200211678 cites W2043461445 @default.
- W4200211678 cites W2046208657 @default.
- W4200211678 cites W2047695409 @default.
- W4200211678 cites W2052474826 @default.
- W4200211678 cites W2055539939 @default.
- W4200211678 cites W2056256068 @default.
- W4200211678 cites W2061623920 @default.
- W4200211678 cites W2068174131 @default.
- W4200211678 cites W2086159572 @default.
- W4200211678 cites W2087484885 @default.
- W4200211678 cites W2089494615 @default.
- W4200211678 cites W2090951884 @default.
- W4200211678 cites W2105960693 @default.
- W4200211678 cites W2107313543 @default.
- W4200211678 cites W2107398421 @default.
- W4200211678 cites W2110926368 @default.
- W4200211678 cites W2141307898 @default.
- W4200211678 cites W2143655754 @default.
- W4200211678 cites W2156098329 @default.
- W4200211678 cites W2194274372 @default.
- W4200211678 cites W2212216121 @default.
- W4200211678 cites W2405171365 @default.
- W4200211678 cites W2461247176 @default.
- W4200211678 cites W2490616499 @default.
- W4200211678 cites W2589580491 @default.
- W4200211678 cites W2592439335 @default.
- W4200211678 cites W2596179513 @default.
- W4200211678 cites W2597059489 @default.
- W4200211678 cites W2609836833 @default.
- W4200211678 cites W2640456656 @default.
- W4200211678 cites W2654759377 @default.
- W4200211678 cites W2743198652 @default.
- W4200211678 cites W2746291808 @default.
- W4200211678 cites W2770109786 @default.
- W4200211678 cites W2790143410 @default.
- W4200211678 cites W2795780364 @default.
- W4200211678 cites W2810168964 @default.
- W4200211678 cites W2894833254 @default.
- W4200211678 cites W2902133661 @default.
- W4200211678 cites W2906218730 @default.
- W4200211678 cites W2923512563 @default.
- W4200211678 cites W2935887347 @default.
- W4200211678 cites W2938328462 @default.
- W4200211678 cites W2962552845 @default.
- W4200211678 cites W2973574388 @default.
- W4200211678 cites W2993973239 @default.
- W4200211678 cites W3003467877 @default.
- W4200211678 cites W3025563006 @default.
- W4200211678 cites W3048252979 @default.
- W4200211678 cites W3091126070 @default.
- W4200211678 cites W3195971522 @default.
- W4200211678 cites W3197692986 @default.
- W4200211678 doi "https://doi.org/10.1016/j.biopha.2021.112460" @default.
- W4200211678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34864314" @default.
- W4200211678 hasPublicationYear "2022" @default.
- W4200211678 type Work @default.
- W4200211678 citedByCount "13" @default.
- W4200211678 countsByYear W42002116782022 @default.
- W4200211678 countsByYear W42002116782023 @default.
- W4200211678 crossrefType "journal-article" @default.
- W4200211678 hasAuthorship W4200211678A5001713307 @default.
- W4200211678 hasAuthorship W4200211678A5008140876 @default.
- W4200211678 hasAuthorship W4200211678A5021398141 @default.
- W4200211678 hasAuthorship W4200211678A5060371031 @default.
- W4200211678 hasAuthorship W4200211678A5064239944 @default.
- W4200211678 hasAuthorship W4200211678A5069220879 @default.
- W4200211678 hasAuthorship W4200211678A5076327210 @default.
- W4200211678 hasAuthorship W4200211678A5087845262 @default.
- W4200211678 hasBestOaLocation W42002116781 @default.
- W4200211678 hasConcept C126322002 @default.
- W4200211678 hasConcept C13373296 @default.
- W4200211678 hasConcept C134018914 @default.
- W4200211678 hasConcept C203014093 @default.
- W4200211678 hasConcept C2776914184 @default.
- W4200211678 hasConcept C2778163477 @default.
- W4200211678 hasConcept C2780072125 @default.